查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1800967

2025-2033年骨质疏鬆症药物市场报告（依产品类型、给药途径及地区）

Osteoporosis Drugs Market Report by Product Type, Route of Administration, and Region 2025-2033
出版日期: | 出版商: IMARC | 英文 144 Pages | 商品交期: 2-3个工作天内

价格

2024年全球骨质疏鬆症药物市场规模达173亿美元。展望未来， IMARC Group预计到2033年市场规模将达到250亿美元，2025-2033年期间的成长率（CAGR）为3.98%。

骨质疏鬆症是一种会导致骨组织和骨强度下降的疾病。诊断方法包括X光、电脑断层扫描（CT）和磁振造影（MRI）。目前市面上有各种不同剂型的药物，从一般药片到静脉注射剂，用于缓解骨质疏鬆症的症状。这些药物有助于恢復骨吸收和骨形成的平衡，修復骨骼的微观缺陷，降低骨折风险，并增强患者的整体肌肉力量。

由于久坐不动的生活方式、过度饮酒和吸烟增多，骨质疏鬆症的盛行率不断上升，这是推动市场成长的关键因素。患有乳糜泻、肾臟病或肝病、癌症、红斑性狼疮、多发性骨髓瘤和类风湿性关节炎的人数不断增加，进一步加速了市场的成长。此外，骨量流失会随着年龄的增长而增加，这增加了老年人骨质疏鬆症的风险。因此，老年人口的增长对全球骨质疏鬆症药物的需求产生了积极影响。此外，一些管理机构正在开发新型疗法，这也促进了市场的成长。例如，美国食品药物管理局 (FDA) 已批准用于治疗骨折风险高或对其他骨质疏鬆症疗法不耐受的停经后女性的新型骨质疏鬆症药物。此外，预计大量处于后期临床试验阶段的药物将在未来几年推动市场成长。

本报告回答的关键问题

  • 全球骨质疏鬆症药物市场有多大？ 2025-2033年全球骨质疏鬆症药物市场的预期成长率为何？
  • 推动全球骨质疏鬆症药物市场发展的关键因素有哪些？
  • COVID-19 对全球骨质疏鬆症药物市场有何影响？
  • 根据产品类型，全球骨质疏鬆症药物市场是如何分布的？
  • 根据给药途径，全球骨质疏鬆症药物市场如何分布？
  • 全球骨质疏鬆症药物市场的主要区域有哪些？
  • 全球骨质疏鬆症药物市场的主要参与者/公司有哪些？

目录

第一章：前言

第二章：范围与方法

  • 研究目标
  • 利害关係人
  • 资料来源
    • 主要来源
    • 次要来源
  • 市场评估
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第三章：执行摘要

第四章：简介

第五章：全球骨质疏鬆症药物市场

  • 市场概览
  • 市场表现
  • COVID-19的影响
  • 市场预测

第六章：市场区隔：依产品类型

  • 双磷酸盐
  • 降钙素
  • Rank 配体抑制剂
  • 副甲状腺素治疗（PTH）
  • 选择性雌激素受体调节剂 (SERM)
  • 硬化蛋白抑制剂
  • 其他的

第七章：市场区隔：依行政途径

  • 口服
  • 注射剂
  • 其他的

第八章：市场区隔：依地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲

第九章：SWOT分析

第 10 章：价值链分析

第 11 章：波特五力分析

第 12 章：价格分析

第 13 章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • Amgen Inc.
    • Eli Lilly and Company
    • F. Hoffmann-La Roche AG
    • GlaxoSmithKline Plc
    • Merck & Co. Inc.
    • Novartis AG
    • Pfizer Inc.
    • Radius Health Inc.
    • Teva Pharmaceutical Industries Ltd.
    • UCB SA
Product Code: SR112025A3104

The global osteoporosis drugs market size reached USD 17.3 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 25.0 Billion by 2033, exhibiting a growth rate (CAGR) of 3.98% during 2025-2033.

Osteoporosis is a disease that causes deterioration of bone tissues and strength. It is diagnosed by performing different scans, such as X-ray, computed tomography (CT) and magnetic resonance imaging (MRI). Various drugs are currently available in different formulations, ranging from regular tablets to intravenous (IV) infusions, for alleviating the symptoms of osteoporosis. These drugs help restore the balance of resorption and formation, repair microscopic defects in bones, reduce the risk of fractures and improve the overall muscle strength of the patients.

The growing prevalence of osteoporosis on account of sedentary lifestyles, excessive consumption of alcohol, and rising utilization of tobacco represent the key factors bolstering the growth of the market. The increasing number of individuals who have celiac disease, kidney or liver disease, cancer, lupus, multiple myeloma and rheumatoid arthritis is further accelerating the market growth. Moreover, bone mass loss increases with age, which raises the risk of developing osteoporosis among older people. Consequently, the rising geriatric population is positively influencing the demand for osteoporosis drugs worldwide. Furthermore, several governing authorities are developing novel therapeutics, which is contributing to the market growth. For instance, the US Food and Drug Administration (FDA) has approved novel osteoporosis drugs for postmenopausal women who are at a high risk of fractures or are intolerant to other osteoporosis therapies. Besides this, a wide range of drugs in late-stage clinical trials is anticipated to propel the market growth in the coming years.

Key Market Segmentation:

Breakup by Product Type:

  • Bisphosphonates
  • Calcitonin
  • Rank Ligand Inhibitor
  • Parathyroid Hormone Therapy (PTH)
  • Selective Estrogen Receptor Modulators (SERMs)
  • Sclerostin Inhibitor
  • Others

Breakup by Route of Administration:

  • Oral
  • Injectable
  • Others

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Amgen Inc., Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline Plc, Merck & Co. Inc., Novartis AG, Pfizer Inc., Radius Health Inc., Teva Pharmaceutical Industries Ltd. and UCB S.A.

Key Questions Answered in This Report

  • 1.How big is the global osteoporosis drugs market?
  • 2.What is the expected growth rate of the global osteoporosis drugs market during 2025-2033?
  • 3.What are the key factors driving the global osteoporosis drugs market?
  • 4.What has been the impact of COVID-19 on the global osteoporosis drugs market?
  • 5.What is the breakup of the global osteoporosis drugs market based on the product type?
  • 6.What is the breakup of the global osteoporosis drugs market based on the route of administration?
  • 7.What are the key regions in the global osteoporosis drugs market?
  • 8.Who are the key players/companies in the global osteoporosis drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Osteoporosis Drugs Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Product Type

  • 6.1 Bisphosphonates
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Calcitonin
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Rank Ligand Inhibitor
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Parathyroid Hormone Therapy (PTH)
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Selective Estrogen Receptor Modulators (SERMs)
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Sclerostin Inhibitor
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast
  • 6.7 Others
    • 6.7.1 Market Trends
    • 6.7.2 Market Forecast

7 Market Breakup by Route of Administration

  • 7.1 Oral
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Injectable
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Others
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast

8 Market Breakup by Region

  • 8.1 North America
    • 8.1.1 United States
      • 8.1.1.1 Market Trends
      • 8.1.1.2 Market Forecast
    • 8.1.2 Canada
      • 8.1.2.1 Market Trends
      • 8.1.2.2 Market Forecast
  • 8.2 Asia-Pacific
    • 8.2.1 China
      • 8.2.1.1 Market Trends
      • 8.2.1.2 Market Forecast
    • 8.2.2 Japan
      • 8.2.2.1 Market Trends
      • 8.2.2.2 Market Forecast
    • 8.2.3 India
      • 8.2.3.1 Market Trends
      • 8.2.3.2 Market Forecast
    • 8.2.4 South Korea
      • 8.2.4.1 Market Trends
      • 8.2.4.2 Market Forecast
    • 8.2.5 Australia
      • 8.2.5.1 Market Trends
      • 8.2.5.2 Market Forecast
    • 8.2.6 Indonesia
      • 8.2.6.1 Market Trends
      • 8.2.6.2 Market Forecast
    • 8.2.7 Others
      • 8.2.7.1 Market Trends
      • 8.2.7.2 Market Forecast
  • 8.3 Europe
    • 8.3.1 Germany
      • 8.3.1.1 Market Trends
      • 8.3.1.2 Market Forecast
    • 8.3.2 France
      • 8.3.2.1 Market Trends
      • 8.3.2.2 Market Forecast
    • 8.3.3 United Kingdom
      • 8.3.3.1 Market Trends
      • 8.3.3.2 Market Forecast
    • 8.3.4 Italy
      • 8.3.4.1 Market Trends
      • 8.3.4.2 Market Forecast
    • 8.3.5 Spain
      • 8.3.5.1 Market Trends
      • 8.3.5.2 Market Forecast
    • 8.3.6 Russia
      • 8.3.6.1 Market Trends
      • 8.3.6.2 Market Forecast
    • 8.3.7 Others
      • 8.3.7.1 Market Trends
      • 8.3.7.2 Market Forecast
  • 8.4 Latin America
    • 8.4.1 Brazil
      • 8.4.1.1 Market Trends
      • 8.4.1.2 Market Forecast
    • 8.4.2 Mexico
      • 8.4.2.1 Market Trends
      • 8.4.2.2 Market Forecast
    • 8.4.3 Others
      • 8.4.3.1 Market Trends
      • 8.4.3.2 Market Forecast
  • 8.5 Middle East and Africa
    • 8.5.1 Market Trends
    • 8.5.2 Market Breakup by Country
    • 8.5.3 Market Forecast

9 SWOT Analysis

  • 9.1 Overview
  • 9.2 Strengths
  • 9.3 Weaknesses
  • 9.4 Opportunities
  • 9.5 Threats

10 Value Chain Analysis

11 Porters Five Forces Analysis

  • 11.1 Overview
  • 11.2 Bargaining Power of Buyers
  • 11.3 Bargaining Power of Suppliers
  • 11.4 Degree of Competition
  • 11.5 Threat of New Entrants
  • 11.6 Threat of Substitutes

12 Price Analysis

13 Competitive Landscape

  • 13.1 Market Structure
  • 13.2 Key Players
  • 13.3 Profiles of Key Players
    • 13.3.1 Amgen Inc.
      • 13.3.1.1 Company Overview
      • 13.3.1.2 Product Portfolio
      • 13.3.1.3 Financials
      • 13.3.1.4 SWOT Analysis
    • 13.3.2 Eli Lilly and Company
      • 13.3.2.1 Company Overview
      • 13.3.2.2 Product Portfolio
      • 13.3.2.3 Financials
      • 13.3.2.4 SWOT Analysis
    • 13.3.3 F. Hoffmann-La Roche AG
      • 13.3.3.1 Company Overview
      • 13.3.3.2 Product Portfolio
      • 13.3.3.3 SWOT Analysis
    • 13.3.4 GlaxoSmithKline Plc
      • 13.3.4.1 Company Overview
      • 13.3.4.2 Product Portfolio
      • 13.3.4.3 Financials
      • 13.3.4.4 SWOT Analysis
    • 13.3.5 Merck & Co. Inc.
      • 13.3.5.1 Company Overview
      • 13.3.5.2 Product Portfolio
      • 13.3.5.3 Financials
      • 13.3.5.4 SWOT Analysis
    • 13.3.6 Novartis AG
      • 13.3.6.1 Company Overview
      • 13.3.6.2 Product Portfolio
      • 13.3.6.3 Financials
      • 13.3.6.4 SWOT Analysis
    • 13.3.7 Pfizer Inc.
      • 13.3.7.1 Company Overview
      • 13.3.7.2 Product Portfolio
      • 13.3.7.3 Financials
      • 13.3.7.4 SWOT Analysis
    • 13.3.8 Radius Health Inc.
      • 13.3.8.1 Company Overview
      • 13.3.8.2 Product Portfolio
      • 13.3.8.3 Financials
    • 13.3.9 Teva Pharmaceutical Industries Ltd.
      • 13.3.9.1 Company Overview
      • 13.3.9.2 Product Portfolio
      • 13.3.9.3 Financials
      • 13.3.9.4 SWOT Analysis
    • 13.3.10 UCB S.A.
      • 13.3.10.1 Company Overview
      • 13.3.10.2 Product Portfolio
      • 13.3.10.3 Financials
      • 13.3.10.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Osteoporosis Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: Osteoporosis Drugs Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Osteoporosis Drugs Market: Breakup by Product Type (in %), 2024
  • Figure 4: Global: Osteoporosis Drugs Market: Breakup by Route of Administration (in %), 2024
  • Figure 5: Global: Osteoporosis Drugs Market: Breakup by Region (in %), 2024
  • Figure 6: Global: Osteoporosis Drugs Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 7: Global: Osteoporosis Drugs (Bisphosphonates) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 8: Global: Osteoporosis Drugs (Bisphosphonates) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 9: Global: Osteoporosis Drugs (Calcitonin) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 10: Global: Osteoporosis Drugs (Calcitonin) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 11: Global: Osteoporosis Drugs (Rank Ligand Inhibitor) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 12: Global: Osteoporosis Drugs (Rank Ligand Inhibitor) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 13: Global: Osteoporosis Drugs (Parathyroid Hormone Therapy- PTH) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 14: Global: Osteoporosis Drugs (Parathyroid Hormone Therapy- PTH) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 15: Global: Osteoporosis Drugs (Selective Estrogen Receptor Modulators- SERMs) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 16: Global: Osteoporosis Drugs (Selective Estrogen Receptor Modulators- SERMs) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 17: Global: Osteoporosis Drugs (Sclerostin Inhibitor) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 18: Global: Osteoporosis Drugs (Sclerostin Inhibitor) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 19: Global: Osteoporosis Drugs (Others) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 20: Global: Osteoporosis Drugs (Others) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 21: Global: Osteoporosis Drugs (Oral) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 22: Global: Osteoporosis Drugs (Oral) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 23: Global: Osteoporosis Drugs (Injectable) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 24: Global: Osteoporosis Drugs (Injectable) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 25: Global: Osteoporosis Drugs (Others) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 26: Global: Osteoporosis Drugs (Others) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 27: North America: Osteoporosis Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 28: North America: Osteoporosis Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 29: United States: Osteoporosis Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 30: United States: Osteoporosis Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 31: Canada: Osteoporosis Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 32: Canada: Osteoporosis Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 33: Asia-Pacific: Osteoporosis Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 34: Asia-Pacific: Osteoporosis Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 35: China: Osteoporosis Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 36: China: Osteoporosis Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 37: Japan: Osteoporosis Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 38: Japan: Osteoporosis Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 39: India: Osteoporosis Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 40: India: Osteoporosis Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 41: South Korea: Osteoporosis Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 42: South Korea: Osteoporosis Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 43: Australia: Osteoporosis Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 44: Australia: Osteoporosis Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 45: Indonesia: Osteoporosis Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 46: Indonesia: Osteoporosis Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 47: Others: Osteoporosis Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 48: Others: Osteoporosis Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 49: Europe: Osteoporosis Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 50: Europe: Osteoporosis Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 51: Germany: Osteoporosis Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 52: Germany: Osteoporosis Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 53: France: Osteoporosis Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 54: France: Osteoporosis Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 55: United Kingdom: Osteoporosis Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 56: United Kingdom: Osteoporosis Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 57: Italy: Osteoporosis Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 58: Italy: Osteoporosis Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 59: Spain: Osteoporosis Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 60: Spain: Osteoporosis Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 61: Russia: Osteoporosis Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 62: Russia: Osteoporosis Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 63: Others: Osteoporosis Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 64: Others: Osteoporosis Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 65: Latin America: Osteoporosis Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 66: Latin America: Osteoporosis Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 67: Brazil: Osteoporosis Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 68: Brazil: Osteoporosis Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 69: Mexico: Osteoporosis Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 70: Mexico: Osteoporosis Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 71: Others: Osteoporosis Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 72: Others: Osteoporosis Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 73: Middle East and Africa: Osteoporosis Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 74: Middle East and Africa: Osteoporosis Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 75: Middle East and Africa: Osteoporosis Drugs Market: Breakup by Country (in %), 2024
  • Figure 76: Global: Osteoporosis Drugs Industry: SWOT Analysis
  • Figure 77: Global: Osteoporosis Drugs Industry: Value Chain Analysis
  • Figure 78: Global: Osteoporosis Drugs Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Osteoporosis Drugs Market: Key Industry Highlights, 2024 and 2033
  • Table 2: Global: Osteoporosis Drugs Market Forecast: Breakup by Product Type (in Million USD), 2025-2033
  • Table 3: Global: Osteoporosis Drugs Market Forecast: Breakup by Route of Administration (in Million USD), 2025-2033
  • Table 4: Global: Osteoporosis Drugs Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 5: Global: Osteoporosis Drugs Market: Competitive Structure
  • Table 6: Global: Osteoporosis Drugs Market: Key Players